Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jan 2019

At a glance

  • Drugs ASP 4345 (Primary) ; Aripiprazole; Brexpiprazole; Lurasidone; Olanzapine; Paliperidone; Quetiapine; Risperidone; Ziprasidone
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Astellas Pharma Global Development
  • Most Recent Events

    • 18 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 21 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top